Royal Bank of Canada
SRNE

Royal Bank of Canada’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Royal Bank of Canada’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-71,411
Closed -$64K – 7796
2022
Q4 		$64K Buy
71,411
+60,677
+565% +$80.5K ﹤0.01% 5754
2022
Q3 		$16K Buy
10,734
+757
+8% +$1.72K ﹤0.01% 6246
2022
Q2 		$20K Sell
9,977
-28,254
-74% -$48.9K ﹤0.01% 6125
2022
Q1 		$88K Sell
38,231
-165,084
-81% -$515K ﹤0.01% 5748
2021
Q4 		$946K Buy
203,315
+152,206
+298% +$945K ﹤0.01% 3874
2021
Q3 		$390K Buy
51,109
+12,767
+33% +$108K ﹤0.01% 4556
2021
Q2 		$372K Buy
38,342
+615
+2% +$4.9K ﹤0.01% 4531
2021
Q1 		$311K Buy
37,727
+7,906
+27% +$83.5K ﹤0.01% 4585
2020
Q4 		$203K Sell
29,821
-8,603
-22% -$69.1K ﹤0.01% 4848
2020
Q3 		$428K Buy
38,424
+22,623
+143% +$207K ﹤0.01% 3997
2020
Q2 		$99K Sell
15,801
-13,045
-45% -$49.9K ﹤0.01% 4851
2020
Q1 		$54K Buy
28,846
+27,721
+2,464% +$79.8K ﹤0.01% 5119
2019
Q4 		$4K Buy
1,125
+1,000
+800% +$2.38K ﹤0.01% 6443
2019
Q3 		$0 Hold
125
– – ﹤0.01% 7287
2019
Q2 		$0 Buy
+125
New +$450 ﹤0.01% 7314
2018
Q4 		– Sell
-8,345
Closed -$37K – 7286
2018
Q3 		$37K Buy
8,345
+3,998
+92% +$22.2K ﹤0.01% 5382
2018
Q2 		$31K Buy
4,347
+3,547
+443% +$24.1K ﹤0.01% 5362
2018
Q1 		$4K Buy
800
+653
+444% +$4.65K ﹤0.01% 6010
2017
Q4 		$1K Buy
147
+114
+345% +$297 ﹤0.01% 6444
2017
Q3 		$0 Sell
33
-4,467
-99% -$8.2K ﹤0.01% 7087
2017
Q2 		$9K Buy
4,500
+3,562
+380% +$6.95K ﹤0.01% 5862
2017
Q1 		$4K Buy
938
+116
+14% +$582 ﹤0.01% 6303
2016
Q4 		$4K Buy
822
+741
+915% +$4.45K ﹤0.01% 6377
2016
Q3 		$1K Buy
+81
New +$545 ﹤0.01% 6325
2016
Q1 		– Sell
-73
Closed -$1K – 6747
2015
Q4 		$1K Sell
73
-1,223
-94% -$10.3K ﹤0.01% 6516
2015
Q3 		$11K Sell
1,296
-242
-16% -$3.85K ﹤0.01% 5858
2015
Q2 		$27K Buy
+1,538
New +$19.8K ﹤0.01% 5555

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Royal Bank of Canada's SRNE Position: Q1 2023 in Review

Royal Bank of Canada sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 71,411 shares — an estimated $64K sold.

Royal Bank of Canada first reported a position in SRNE in Q2 2015 and held it in 27 quarters. The position peaked at $946K in Q4 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Royal Bank of Canada reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Royal Bank of Canada sold 71,411 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $64K.
  • Royal Bank of Canada first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 27 quarters.
  • Royal Bank of Canada's Sorrento Therapeutics, Inc. position peaked at $946K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Royal Bank of Canada's 13F filing for Q1 2023, filed 15 May 2023.